Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
During the webcast and conference call, senior leaders will provide an overview of Legend Biotech's performance for the quarter.
Investors and other interested parties may join the live audio webcast of the call via this weblink.
A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech's website under the Events and Presentation section approximately two hours after the call concludes.
ABOUT LEGEND BIOTECH
Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell (gd T) and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of cutting-edge therapeutics for patients worldwide.
GRAIL, LLC., a healthcare company whose mission is to detect cancer early when it can be cured, today will host a virtual Capital Markets Day. Members from GRAIL's management team will outline growth drivers for Galleri®, a clinically validated,...
Quince Therapeutics, Inc. , a late-stage biotechnology company developing an innovative drug delivery technology designed to leverage a patient's own biology to deliver rare disease therapeutics, today provided an update on the company's development...
Harrow , a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for...
Incyte Corporation (the "Company") today announced that its Board of Directors approved a share repurchase authorization of $2.0 billion. The Company has commenced a modified "Dutch Auction" tender offer to repurchase shares of its common stock for...
D-Wave Quantum Inc., ("D-Wave" or the "Company") a leader in commercial quantum computing systems, software, and services, today announced financial results for its first fiscal quarter ended March 31, 2024.
"D-Wave's first quarter revenue and...
Xperi Inc. (the "Company" or "Xperi") today announced that leading proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that Xperi stockholders vote "FOR" all of the Company's nominees on the BLUE proxy card ahead of the...
